Returning guest, Dr. Andrew (Andy) Krivoshik, MD, Ph.D., SVP, and Oncology Therapeutic Head for Astellas Oncology shares his perspective on this year’s C3 Prize (Changing Cancer Care). He elaborates on his own journey and reflects on why programs like this are needed more than ever in these unprecedented times. The C3 Prize is a global challenge to advance ideas beyond medicine that can make a big impact in the cancer community. The program will award $200,000 in grants and resources to help winners further advance their ideas. The award is open to anyone with a great idea including concepts that can ease the increased burden of the COVID-19 pandemic on cancer care and health disparities affecting cancer patients and caregivers. Applications are open from now until September 28, 2020.
Andrew P. Krivoshik began his career in academic medicine, often balancing time in the lab with time seeing patients in the clinic. Now Senior Vice President and Oncology Therapeutic Head of Astellas Pharma US, his career is focused on pharmaceutical development to help serve more patients and make a greater impact in their care. Dr. Krivoshik has expertise in global clinical development including implementing novel and innovative clinical trial designs, is a subject matter expert and primary author of clinical protocols, investigator brochures, and regulatory submissions spanning the life cycle of clinical development, and is an invited speaker and session chair at international scientific congresses.